【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables15
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 28
3.1.3 Prognosis 29
3.2 Symptoms 29
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 31
4.1.1 The risk of contracting HCV is almost 50 times higher among injection drug users 32
4.1.2 There is a 10.9-fold increased risk of developing HCV infection through a blood transfusion 33
4.1.3 No current preventative therapy to reduce perinatal HCV transmission 33
4.1.4 Metabolic syndrome is a common comorbidity in HCV-infected individuals 34
4.1.5 Chronic alcoholism greatly magnifies the risk of HCC 35
4.1.6 HBV and HCV share similar modes of transmission, resulting in co-infection 35
4.1.7 HCV/HIV co-infection complicates treatment options and accelerates liver damage 35
4.2 Global Trends 36
4.2.1 US 37
4.2.2 5EU 38
4.2.3 Japan 41
4.2.4 Brazil 41
4.2.5 China 42
4.3 Forecast Methodology 43
4.3.1 Sources Used 43
4.3.2 Forecast Assumptions and Methods 47
4.3.3 Forecast Assumptions and Methods (HCV Genotypes) 51
4.3.4 Sources Not Used 55
4.4 Epidemiology Forecast for HCV (2012-2022) 55
4.4.1 Total Prevalent Cases of HCV 55
4.4.2 Age-Specific Prevalent Cases of HCV 58
4.4.3 Sex-Specific Prevalent Cases of HCV 61
4.4.4 Age-Standardized Prevalence of HCV 64
4.4.5 HCV Genotype Class Distributions 66
4.5 Discussion 67
4.5.1 Conclusion on Epidemiology Trends 67
4.5.2 Limitations of the Analysis 68
4.5.3 Strengths of the Analysis 69
5 Disease Management 70
5.1 Diagnosis and Referral Overview 70
5.2 Treatment Overview 71
5.3 US 74
5.3.1 Diagnosis 74
5.3.2 Clinical Practice 76
5.4 France 79
5.4.1 Diagnosis 79
5.4.2 Clinical Practice 80
5.5 Germany 81
5.5.1 Diagnosis 81
5.5.2 Clinical Practice 82
5.6 Italy 83
5.6.1 Diagnosis 83
5.6.2 Clinical Practice 83
5.7 Spain 84
5.7.1 Diagnosis 84
5.7.2 Clinical Practice 84
5.8 UK 86
5.8.1 Diagnosis 86
5.8.2 Clinical Practice 87
5.9 Japan 88
5.9.1 Diagnosis 88
5.9.2 Clinical Practice 88
5.10 Brazil 89
5.10.1 Diagnosis 89
5.10.2 Clinical Practice 90
5.11 China 90
5.11.1 Diagnosis 90
5.11.2 Clinical Practice 91
6 Competitive Assessment 92
6.1 Overview 92
6.2 Strategic Competitor Assessment 92
6.3 Product Profiles – Major Brands 94
6.3.1 Sovaldi and Sovaldi/Ledipasvir 94
6.3.2 Olysio 106
6.3.3 Incivek 114
6.3.4 Victrelis 121
6.3.5 Pegasys 127
6.3.6 PegIntron 133
6.3.7 Copegus, Rebetol, and Generic Ribavirin 139
6.3.8 Therapeutic Class: Interferon 144
7 Opportunity and Unmet Need 145
7.1 Overview 145
7.2 Unmet Needs 146
7.2.1 Unmet Need: Enhanced Efficacy in Difficult-to-Treat Patient Populations 146
7.2.2 Unmet Need: Improved Understanding of Drug-Drug Interactions 147
7.2.3 Unmet Need: Increased Disease Awareness and Diagnosis of HCV 148
7.2.4 Unmet Need: Reduced Cost of All-Oral Regimens 149
7.2.5 Unmet Need: Improved Treatment Tolerability 149
7.2.6 Unmet Need: Simplified Treatment Algorithm 150
7.2.7 Unmet Need: Shorter Treatment Duration 151
7.3 Unmet Needs Gap Analysis 152
7.4 Opportunities 153
7.4.1 Opportunity: Develop a Pan-Genotypic, All-Oral HCV Regimen 153
7.4.2 Opportunity: Target Difficult-to-Treat Patient Populations 153
7.4.3 Opportunity: Eliminate Ribavirin from All-Oral Regimens 154
7.4.4 Opportunity: Involvement of the Immune System 155
8 Pipeline Assessment 156
8.1 Overview 156
8.2 Clinical Trial Mapping 157
8.2.1 Clinical Trials by Country 157
8.3 Clinical Trials by Phase and Trial Status 158
8.4 Promising Direct-Acting Antivirals (DAAs) in Clinical Development 160
8.4.1 ABT-450/Ombitasvir + Dasabuvir 162
8.4.2 Faldaprevir 172
8.4.3 Daclatasvir, Daclatasvir + Asunaprevir, and Daclatasvir/Asunaprevir/BMS-791325 181
8.4.4 MK-5172/MK-8742 194
8.4.5 Vaniprevir 202
8.5 Other Drug Classes in Clinical Development 208
8.5.1 Interferon Derivatives 208
8.5.2 Host-Targeting Therapies 210
9 Current and Future Players 212
9.1 Overview 212
9.2 Trends in Corporate Strategy 214
9.3 Company Profiles 216
9.3.1 Merck 216
9.3.2 Roche 218
9.3.3 Vertex 221
9.3.4 Janssen 224
9.3.5 Gilead 226
9.3.6 AbbVie 231
9.3.7 Bristol-Myers Squibb 233
9.3.8 Boehringer Ingelheim 236
9.4 Additional Companies with Promising Drugs 239
9.4.1 Mitsubishi Tanabe Pharmaceutical Corporation 239
9.4.2 Achillion 240
9.4.3 Scynexis 241
9.4.4 Idenix 242
9.4.5 Presidio 243
9.4.6 Novartis 244
10 Market Outlook 246
10.1 Global Markets 246
10.1.1 Forecast 246
10.1.2 Drivers and Barriers – Global Issues 250
10.2 US 255
10.2.1 Forecast 255
10.2.2 Key Events 261
10.2.3 Drivers and Barriers 262
10.3 France 266
10.3.1 Forecast 266
10.3.2 Key Events 272
10.3.3 Drivers and Barriers 273
10.4 Germany 275
10.4.1 Forecast 275
10.4.2 Key Events 280
10.4.3 Drivers and Barriers 281
10.5 Italy 283
10.5.1 Forecast 283
10.5.2 Key Events 287
10.5.3 Drivers and Barriers 288
10.6 Spain 290
10.6.1 Forecast 290
10.6.2 Key Events 294
10.6.3 Drivers and Barriers 295
10.7 UK 297
10.7.1 Forecast 297
10.7.2 Key Events 302
10.7.3 Drivers and Barriers 303
10.8 Japan 305
10.8.1 Forecast 305
10.8.2 Key Events 311
10.8.3 Drivers and Barriers 312
10.9 Brazil 314
10.9.1 Forecast 314
10.9.2 Key Events 318
10.9.3 Drivers and Barriers 318
10.10 China 321
10.10.1 Forecast 321
10.10.2 Key Events 325
10.10.3 Drivers and Barriers 325
11 Appendix 328
11.1 Bibliography 328
11.2 Abbreviations 358
11.3 Methodology 361
11.4 Forecasting Methodology 361
11.4.1 Percent Drug-Treated Patients 361
11.4.2 Patient Warehousing 362
11.4.3 Drugs Included in Each Therapeutic Class 362
11.4.4 Launch and Patent Expiry Dates 363
11.4.5 General Pricing Assumptions 364
11.4.6 Individual Drug Assumptions 365
11.4.7 Generic Erosion 369
11.4.8 Selection of Pipeline Agents 369
11.4.9 Pricing of Pipeline Agents 370
11.5 Physicians and Specialists Included in This Study 374
11.6 Survey of Prescribing Physicians 376
11.7 About the Authors 377
11.7.1 Analysts 377
11.7.2 Epidemiologist 378
11.7.3 Therapy Area Director 378
11.7.4 Global Head of Healthcare 379
11.8 About GlobalData 380
11.9 Disclaimer 380
【レポート販売概要】
■ タイトル：C型肝炎ウイルス感染：グローバル治療薬の市場予測と分析■ 英文：PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
■ 発行日：2014年5月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC001EPIDR
■ 調査対象地域：グローバル
- グローバル空港産業サーベイ（2013-2014）：市場動向、マーケティング戦略Why was the report written? This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading global airport industry executives. The report provides data and analysis on global airports industry suppliers’ media spend, marketing and sales strategies, and practices and business planning within the global airports industry. This report includes key topics such as …
- 発泡スチロール（EPS）の世界市場About Expanded PolystyreneExpanded polystyrene is made from solid beads of polystyrene, which are thermoplastic resins produced from the emulsion polymerization of the monomer, styrene. It is a rigid transparent thermoplastic with good electrical insulating properties and physical properties. It is used in molders products, sheet materials, and foams. Technavio’s analysts forecast the global expan …
- 食品着色料の世界市場予測（～2023年）：天然、合成、ネイチャーアイデンティカル“The food colors market is projected to grow at a CAGR of 5.7%.” The food colors market is estimated at USD 3.88 billion in 2018 and is projected to reach USD 5.12 billion by 2023. It is projected to grow at a CAGR of 5.7% from 2018 to 2023. The market is primarily driven by trends such as growth in consumer awareness regarding food safety and diseases caused by consuming harmful synthetic colors. …
- 高気圧酸素療法（HBOT）装置/機器の世界市場分析：製品別（モノプレース、マルチプレース、局所HBOTデバイス）、用途別（創傷治癒、感染治療、ガス塞栓症）、セグメント予測、2014-2025The global hyperbaric oxygen therapy devices market is expected to reach USD 3.91 billion by 2025, according to a new report by Grand View Research, Inc. Growing inclination of healthcare professionals toward oxygen therapy, despite a lack of conclusive evidence is one of the key factors expected to drive the market over the coming few years.Although the off-label usage of HBOT devices in various …
- 世界の家電業界におけるトランスフォーマー（Transformer）市場（2012-2017）TechNavio's analysts forecast the Global Transformer market in the Consumer Electronics industry to grow at a CAGR of 11.37 percent over the period 2012-2017. One of the key factors contributing to this market growth is the increasing adoption of electronic gadgets. The Global Transformer market in the Consumer Electronics industry has also been witnessing the increasing miniaturization of transfo …
- 指向性エネルギー兵器（DEW）の世界市場予測（～2021年）The directed energy weapons market is projected to grow from USD 6.87 Billion in 2016 to USD 24.45 Billion by 2021, at a CAGR of 28.90% during the forecast period. In recent years, the range of advanced offensive and defensive capabilities offered by smart weapons has made them an indispensable component of any military force. This has created an increased demand for directed energy weapons from v …
- 保護フィルムの世界市場予測（～2022年）The protective films market is projected to reach USD 17.57 billion by 2022, at a CAGR of 6.23% from 2017 to 2022. Increasing demand for protective films from the building and construction industry and the transportation industry especially from the automotive sector are the major drivers for the growth of the protective films market. The difficulty in recycling polymer based protective films act …
- アメリカの運動選手用フットウェア市場About the Athletic Footwear Market in the US The growing health-consciousness and the need for physical fitness are propelling the demand for running shoes in the US. With changes in lifestyles, most US consumers now prefer comfort over price. As a result, the demand for comfortable footwear is increasing, which will also drive the growth of the market in the coming years. The availability of and …
- コグニティブコラボレーションの世界市場予測（～2024年）The cognitive collaboration market is expected to grow at a CAGR of 11.0% during the forecast period due to ease in integration with the already existing environment and increasing need for mobility and collaboration The global cognitive collaboration market size is expected to grow from USD 983 million in 2019 to USD 1,660 million by 2024, at a Compound Annual Growth Rate (CAGR) of 11.0% during t …
- 便座の世界市場2017-2021About Toilet Seats The global toilet seat market is witnessing regional disparities due to cultural differences across the global market. The market focus is shifting to electronic toilet seats from non-electronic toilets seats in the last few years. Japan is one of the leading countries that manufacture high-tech intelligent toilet seats, which experience strong demand from countries such as Chin …
- 低電力広域通信網（WAN）の世界市場予測（～2021）The Low Power Wide Area Network (LPWAN) market size is expected to grow from USD 1.01 Billion in 2016 to USD 24.46 Billion by 2021, at an estimated Compound Annual Growth Rate (CAGR) of 89.3% during the forecast period. Major growth drivers of the LPWAN market are increasing adoption of IoT/M2M devices, rising need of long range connectivity between these devices, and low power and low cost of LPW …
- 産業用ポンプの世界市場分析：製品別（遠心、往復、ロータリー、ダイアフラム）、用途別（石油・ガス、化学、建設、電力、水･廃水処理）、地域別（北アメリカ、ヨーロッパ）、セグメント予測、2014-2025The global industrial pumps market is expected to reach USD 88.43 billion by 2025, according to a new report by Grand View Research, Inc. Increasing product energy use pumps for the extraction and transport of oil and natural gas is expected to have a positive impact on the market per the next nine years. High crude oil prices will fuel the energy sector's revenue, thereby resulting in more demand …
- スタート・ストップバッテリーの世界市場2018-2022105 pages, October 2018 About this market Majority of EVs rely on lithium- ion battery technology for start, light and ignition (SLI) application. These batteries are dependent on metals such as lithium and a mix of cobalt, manganese, nickel, and graphite. According to our industry experts, material sourcing for battery manufacturing has been difficult, to overcome such issues, manufactures like t …
- 鎮痛薬の世界市場2016-2020About the Analgesics Market Analgesics are among the most commonly prescribed drugs for pain, especially that from fractures, ankle sprains, and other injuries. These are designed particularly for pain relief. Opioids, NSAIDs, and local anesthetics are the major analgesics used to treat pain. The long term use of analgesics has been linked to gastrointestinal problems. Pain is treated with analges …
- フレークアイス製氷機の世界市場2017-2021About ice flakerAn ice flaker is a continuous-type ice maker that freezes and dispenses irregular bits of ice simultaneously. Flake ice can be either scale or granular ice. Most flake machines use a stationary evaporator. Flake ice is constantly scraped from the evaporator walls of the ice making machine by a slowly rotating auger. Technavio’s analysts forecast the global ice flaker market to grow …
